Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Corsica Health vs Vea Health

Corsica Health
Graded #188

Higher grade

vs+11.299999999999997
Vea Health
Graded #450

Lower grade

The verdict

Corsica Health takes it — 66.3/100 to 55/100.

Corsica Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCorsica Health +3
48
45
Dose & formulationCorsica Health +26
77
51
Clinical oversightCorsica Health +21
87
66
Labs & monitoringCorsica Health +2
54
52
FulfillmentCorsica Health +7
75
68
Contract termsEven
55
55
Corsica Health · left barVea Health · right bar

The numbers

MetricCorsica HealthVea Health
WeighScore66.3/10055/100
GradeCC
Scorecard rank#188#450
Semaglutide$249/mo (compounded)Not disclosed
Tirzepatide$349/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Corsica Health

Graded #188 · C

Strengths

  • Public pricing shown for both compounded and brand-name options — a real transparency advantage
  • $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
  • LegitScript Certified
  • Clear 3-step intake: Assessment, Provider Review, Receive Medication
  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced

Where it loses points

  • Legal entity name and state of incorporation not disclosed on the site
  • Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
  • Per-state availability not listed publicly
  • First-month promotional pricing not disclosed
  • Lab-work inclusion not clearly disclosed
Vea Health

Graded #450 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard